Navigation Links
AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
Date:10/3/2008

control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

http://www.amtbiopharma.com


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Incorporated Announces Third Quarter 2007 Financial Results
3. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
4. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
7. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
8. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
9. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
10. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
11. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... and PARIS , Sept. 30, ... Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that ... therapy that blocks IL-4 and IL-13 signaling, met all ... sinusitis with nasal polyps (CSwNP) who did not respond ... the potential of dupilumab for use in the treatment ...
(Date:9/29/2014)... Sept. 29, 2014  Repeated exposure to broad-spectrum antibiotics ... with early childhood obesity, say researchers from The Children,s ... retrospective study based on data from electronic health records ... The researchers found that children with four or more ... more likely to be at risk for obesity. The ...
(Date:9/29/2014)... et SAN DIEGO ... Company, Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) ... aujourd,hui la conclusion d,un accord de fusion définitif ... la totalité des actions ordinaires en circulation d,Ambit ... par le biais d,une offre publique d,achat qui ...
Breaking Medicine Technology:Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... , NEW YORK, Nov. 10 Reportlinker.com ... is available in its catalogue. , ... http://www.reportlinker.com/p0161946/Metabolic-Endocrinology-Hypocalcemia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life ... information on the current drug pipeline. This ...
... Life Spine announced today the launch of the AVATAR ... The AVATAR MIS System provides a unique approach to ... delivery system with a variety of rod insertion mechanisms, ... as well as pathologies requiring in-situ reduction, distraction, and ...
Cached Medicine Technology:Reportlinker Adds Metabolic Endocrinology Hypocalcemia 2Reportlinker Adds Metabolic Endocrinology Hypocalcemia 3
(Date:9/29/2014)... CuteBobble.com, an experienced supplier that provides ... new collection of custom bobbleheads for Christmas. ... these quality items. Moreover, all the company’s old and ... code: 10USDOFF). The promotion will last until December 15, ... new designs of custom bobbleheads . Now, our ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Shoulder pain is ... those with persistent shoulder pain generates nearly ¾ of the ... 20-33% of all adults will experience shoulder pain, and of ... has also been reported that 1 in 4 people with ... less than a year. , “This is a real problem, ...
(Date:9/29/2014)... FL (PRWEB) September 30, 2014 Only ... than $20 can improve well-being, says Sublime Beauty®.The secret ... in Skin Brushes and have introduced thousands to this ... , Heshelow was interviewed recently on the eHealth ... to learn more . , "We have just released ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Foundations Recovery ... to announce the start of its 40th national conference ... Greenwald as a featured keynote speaker at the Moments ... experts specializing in the fields of addiction and mental ... Palm Beach, Fla., September 29 – October 2, 2014, ...
(Date:9/29/2014)... Atlanta, GA (PRWEB) September 30, 2014 In ... Whiter Image Dental has recently implemented some principles from the ... company as a whole. Whiter Image CEO Brad Stevens ... the “Most eye-opening seminar [he had] ever been to.” The ... business leaders produce great results by tapping into the desire ...
Breaking Medicine News(10 mins):Health News:Customers Can Get $10 Discount Coupons For Christmas When Ordering Custom Bobbleheads At CuteBobble.com 2Health News:KORT Physical Therapist Shines a Light on Shoulder Pain and Latest Treatments 2Health News:7 Easy Steps to Skin Brushing Guide Available from Sublime Beauty®; Body Brushing Details Revealed in eHealth Radio Network Interview 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Whiter Image Launches Four Disciplines of Execution Initiative into Corporate Strategy 2
... 2009 The world,s top lung cancer specialists, medical ... Francisco, CA for the 13th World Conference on Lung ... Study of Lung Cancer (IASLC). Prevention and early detection ... remains one of the hardest cancers to detect in ...
... ... , ... August 2, 2009 -- United Benefit Advisors, LLC (UBA), one of the nation,s leading ... health management. , , , , ,"The majority of employers clearly recognize the potential ...
... cancer patients who have progressed on a cetuximab-containing regimen ... reported today at the annual meeting of the International ... cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth ... once a patient progresses on one EGFR inhibitor they ...
... FRANCISCO, August 1, 2009 The world,s top lung ... week in San Francisco, CA for the 13th World ... Association for the Study of Lung Cancer (IASLC). According ... WCLC, targeted therapies, as first-line treatment, have the potential ...
... FASTRACK ... Billing & Home HealthCare Agency Billing Software System. The FASTRACK Integrated IV, HME ... single common Microsoft SQL database that allows for the connection of remote sites via ... ...
... ... by Richard K. Riegelman, is hard-wired to the Association of American Colleges ... The book is an important part of a growing movement of several ... as a critical component of good citizenship and a prerequisite for taking ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 2Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 3Health News:Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:Fastrack Release First Integrated HME Billing, Infusion Pharmacy & Home Care Agency Software in a Microsoft Environment 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: